Announced details
Treatment of solid tumors
No dose-limiting toxicities in the Phase I trial (19 patients); T1/2 of 7.9–12.8 hours; best overall assessment of SD in 4 patients and PR in 1 patient. Antitumor effects were confirmed in nonclinical studies with monotherapy and in combination with an immune checkpoint inhibitor (ICI).
19 patients in the domestic Phase I trial (number of patients enrolled in the trial)
Kaken Pharmaceutical presented the results of its nonclinical studies and domestic Phase I trial of KP-483 at this conference.
A conference at which clinical research results on solid tumors and other cancers are presented. The 2026 conference was held in Chicago, United States.
jRCT2031220311 (registration number for the domestic Phase I trial)
Kaken Pharmaceutical headquarters: Bunkyo-ku, Tokyo
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
American Society of Clinical Oncology (ASCO) 2026、Abstract No.2659
| Item | Details |
|---|---|
| Names of Products / Services Covered | KP-483 |
| Counterparty | American Society of Clinical Oncology (ASCO) |
| Counterparty overview | A conference at which clinical research results on solid tumors and other cancers are presented. The 2026 conference was held in Chicago, United States. |
| Relationship with the Company | Kaken Pharmaceutical presented the results of its nonclinical studies and domestic Phase I trial of KP-483 at this conference. |
| Launch date | 29 May–2 June 2026 (the period of ASCO 2026; presentation completed) |
| Applicable area | Treatment of solid tumors |
| Registration number and expiry date | jRCT2031220311 (registration number for the domestic Phase I trial) |
| Location | Kaken Pharmaceutical headquarters: Bunkyo-ku, Tokyo |
| Quantitative Effects | No dose-limiting toxicities in the Phase I trial (19 patients); T1/2 of 7.9–12.8 hours; best overall assessment of SD in 4 patients and PR in 1 patient. Antitumor effects were confirmed in nonclinical studies with monotherapy and in combination with an immune checkpoint inhibitor (ICI). |
| Usage history | 19 patients in the domestic Phase I trial (number of patients enrolled in the trial) |
| Source | American Society of Clinical Oncology (ASCO) 2026、Abstract No.2659 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results were presented at ASCO 2026. The trial was conducted to assess the safety, preliminary pharmacokinetics and efficacy of once-daily oral administration of KP-483.